Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (8.000.000 €): Zusammenarbeit zur Prävention und Behandlung von MDR-Bakterieninfektionen Hor01.11.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Text
Zusammenarbeit zur Prävention und Behandlung von MDR-Bakterieninfektionen
The loss of antibiotic effectiveness due to increasing antimicrobial resistance (AMR) is a serious threat to global public health. The IMI2 AMR Accelerator will develop new agents to treat and prevent infections caused by MDR and XDR bacteria, including Mycobacterium tuberculosis and non-tuberculous mycobacteria. The COMBINE proposal addresses Pillar A, the Capability Building Network (CBN) of the AMR Accelerator programme. The COMBINE consortium will form a Coordination and Support Office (CSO) that will support the delivery of projects across the AMR Accelerator, as well as with efficient communication among projects of the Accelerator and within the AMR community. In addition, we will establish an IT infrastructure that will allow for the FAIRification, collection, aggregation, storage, sharing, and analysis of vaccine and antibacterial preclinical and clinical data sets. When setting up the CSO, we will build on learnings from the two IMI ND4BB projects: ENABLE (an antibacterial discovery and development engine) and TRANSLOCATION (which has built an information centre for data sharing). COMBINE partners will work to accelerate scientific discoveries in the AMR field by optimisation and standardisation of animal infection models, and development of improved models for translation of preclinical animal efficacy data and statistical analysis of clinical data. This will set new standards for the translational and predictive relevance of preclinical data and facilitate optimized design for new clinical trials. Results will feed into study and trial design throughout the AMR Accelerator to achieve more stringent and reliable development programmes.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Asclepia Outsourcing Solutions | 338.228 € |
| Beam Alliance | 113.255 € |
| BIOCOM INTERRELATIONS GmbH | 396.289 € |
| BIOCOM MEDIA AG | 301.212 € |
| BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL | 1.466.860 € |
| EVOTEC INTERNATIONAL GmbH | 0,00 € |
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 800.000 € |
| Glaxosmithkline Research & Development Ltd. | 0,00 € |
| Gritsystems AS | 800.625 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| Statens Serum Institut | 1.070.500 € |
| Uppsala Universitet | 2.713.031 € |
Quelle: https://cordis.europa.eu/project/id/853967
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Asclepia Outsourcing Solutions - EU-Förderung (8.000.000 €): Zusammenarbeit zur Prävention und Behandlung von MDR-Bakterieninfektionen"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
